A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. TPS190-TPS190 ◽  
Author(s):  
D. E. Rathkopf ◽  
D. C. Danila ◽  
S. F. Slovin ◽  
M. J. Morris ◽  
J. E. Steinbrecher ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase I ◽  
Proof Of Concept ◽  
Castration Resistant Prostate Cancer ◽  
Open Label ◽  
Concept Study ◽  
Castration Resistant ◽  
Open Label Phase

scholarly journals Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases

The Prostate ◽  
2019 ◽  
Vol 79 (14) ◽  
pp. 1683-1691 ◽  
Author(s):  
Oliver Sartor ◽  
Daniel Heinrich ◽  
Neil Mariados ◽  
Maria José Méndez Vidal ◽  
Daniel Keizman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Phase 1 ◽  
Castration Resistant Prostate Cancer ◽  
Open Label ◽  
Castration Resistant ◽  
Radium 223 ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document